Drug Discovery World

JULY 2, 2024

So, in this way there is a cross fertilisation from the bigger companies to newer ones. Start-ups will also take drug candidates from the pharma companies that are not getting attention for one reason or another and develop those into viable commercial products.”

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

JULY 18, 2022

Troy Groetken of intellectual property and technology law firm McAndrews, Held & Malloy tells Lu Rahman how pharma companies can take this data from where it currently stands (drug design and development) to a more clinical level. Groetken sees many opportunities to utilise big data and AI in pharma.

Clinical Trials 130

Clinical Trials Therapies Pharmaceuticals Science 130

Predictive Oncology

FEBRUARY 7, 2023

“We’re providing that richness of tumor diversity and the population diversity that normally the companies will not be able to see until they are in a clinical trial and [the drug is] challenged against a multitude of different patients.”

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 52

Drug Discovery World

OCTOBER 16, 2023

The campus is home to GSK, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva, alongside a growing cluster of start-up companies which together have raised £2.9 Next, Saleko highligts how Northumberland and the North East of the UK are recognised for pharmaceutical manufacturing prowess. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

NOVEMBER 16, 2022

Here, DDW’s Reece Armstrong speaks to Dan O’Connor, VP of drug discovery at Molecular Devices, about what the OIC offers to pharmaceutical companies and the advantages and barriers of 3D biology. . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D . The benefits to drug development are obvious then.

Pharma Companies 243

Pharma Companies Science Research Drugs 243

The Pharma Data

DECEMBER 23, 2020

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers. development pipeline for ME/CFS. All study subjects will receive the same Ampligen treatments. See: PLOS ONE ).

Clinical Trials 52

Clinical Trials Trials Virus International 52

The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. More recently, the university has released news of its collaboration with Thermo Fisher Scientific as it looks to discover an immune Covid-19 response pre- and post-vaccination.

Vaccine 52

Vaccine Immune Response Pharma Companies Virus 52

The Pharma Data

NOVEMBER 27, 2020

This week, another pharma company revealed a new technology device that can detect if a patient is infectious or not, while the Russian government published results of its Sputnik V vaccine, claiming it is more than 95 per cent efficient 42 days after the first dose.

Virus 52

Virus Vaccine International Immune Response 52

Advarra

JULY 19, 2022

The sponsor is the pharmaceutical company conducting the trial. If you mean using a different contract research organization (CRO) for the different phases of clinical trials – that’s different. Also consider CRO oversight, trial management, data handling and record keeping, as well as allocation of responsibilities.

Packaging 52

Packaging FDA Regulations Trials 52

Drug Discovery World

MAY 7, 2024

It’s doing this by collaborating with companies and providing access to expertise and facilities across 11 specialist research platforms that include things like organoid development, human challenge models, diagnostics, randomised controlled trials, hits to leads and more.

Vaccine 147

Vaccine Pharmaceutical Companies Clinical Trials Trials 147

DrugBank

JUNE 27, 2024

Currently, about one-third of recent drug approvals and 25% of the pharmaceutical industry's annual revenue is coming from repurposed drugs.This trend is being championed industry-wide, by public organizations and nonprofits, with numerous small companies diving in and academic publications on the subject showing great popularity.  

Drugs 72

Drugs Pharma Companies Computational Chemistry Clinical Trials 72

Drug Discovery World

JANUARY 26, 2023

DDW Editor Reece Armstrong takes a look at the pharmaceutical research and development market in 2023 and asks key opinion leaders what challenges and trends will emerge throughout the year. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.

Clinical Trials 246

Clinical Trials Drugs Trials Therapies 246

Drug Discovery World

JANUARY 5, 2023

There is a real danger for companies simply reacting to the latest EMA mandates, such as the specifics of how data will look under the EU’s eventual implementation of Identification of Medicinal Products (IDMP), and the perceived ‘watering down’ of data-driven process requirements via the shift to Digital Application Dataset Integration (DADI).

Pharma Companies 130

Pharma Companies International Compliance Production 130

The Open Targets Blog

OCTOBER 24, 2023

Several key publications have shown that medicines with genetic evidence to support the link between target and disease have a higher chance of success in clinical trials, especially phase II safety trials.  We released the package on my personal GitHub so that I could keep updating it in the future.

Bioinformatics 64

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 64

Drug Discovery World

AUGUST 16, 2022

These observations may come to light in the clinic, but these disparities can be attributed to every phase of the drug development pipeline – clinical trials, translational research and, ultimately, drug discovery. . Additionally, the lack of diversity in patients participating in clinical trials can also contribute to cancer disparities.

Research 130

Research Clinical Trials Trials Drug Development 130

Altus Drug Development

JUNE 28, 2022

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Production 52

Codon

FEBRUARY 13, 2024

1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. No phage-based therapeutic has reached the latter stages of the clinical trial pipeline (where promising results lead to an expanded trial involving thousands of patients).

Therapies 128

Therapies DNA Virus Clinical Trials 128

Drug Discovery World

SEPTEMBER 7, 2022

The drug discovery and development process is costly and arduous, offering no certainty of success which often rests on whether a company has chosen the correct drug molecule and target. The pharmaceutical industry is built on data. The challenge of data . We see a strongly increased demand for our solutions,” Dr Kusserow says. .

Research 130

Research Clinical Trials Pharmaceutical Companies Pharma Companies 130

The Pharma Data

OCTOBER 14, 2020

AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm. In this 24-week clinical trial, lanifibranor met the primary endpoint with a statistically significant reduction of the Steatosis Activity Fibrosis score.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

DECEMBER 30, 2020

In September 2020, the trials were halted to investigate a potentially severe side effect in a UK patient, transverse myelitis, an inflammation of part of the spinal cord. After a short break, the trial restarted in the UK and other parts of the world, but was delayed for much longer in the U.S. M&A.

Vaccine 52

Vaccine FDA Trials Therapies 52